NIH: When Subawards are Not Active in All Budget Periods of the Prime Applicant

• Correction to the General Application Guide SF424(R&R) (*next iteration of Guide will include correction*)
• While subcontract may be for only 1 year, the budget periods for the sub should match the prime applicant budget period
• Notice outlines NEW instructions for inactive budget periods.

Updated Inclusion Enrollment Format for RPPR Submission

RPPR (Research Performance Progress Report)

• NIH transitioned to the new eRA Inclusion Management System (IMS) and updated the reporting format for reporting enrollment by sex/gender, race, and ethnicity.

• If project is required to monitor inclusion, users must go to Inclusion Link in RPPR and update the record.

• Submissions AFTER March 5th must be updated into the new enrollment format in the IMS.

New Way to Tell if Your Application Falls Within a Direct Cost Limit

• A new “Total Direct Costs Less Consortium F&A” table has been added to the assembled application for all NIH applications that use the R&R Budget form and include subaward budgets. The table can be used to determine if your application (by NIH calculations) falls within a direct cost limit. It is located after the last subaward budget in single project applications and with the Composite Application Budget Summary in multi-project applications.
• Currently R&R Budget forms (unlike the PHS 398 Modular Budget form) do not include a “Direct Cost less Consortium F&A” line item.
• Not having this line makes it hard to tell if your application is compliant with the limits.

<table>
<thead>
<tr>
<th>Category</th>
<th>Budget Period 1</th>
<th>Budget Period 2</th>
<th>Budget Period 3</th>
<th>Budget Period 4</th>
<th>Budget Period 5</th>
<th>TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Direct Costs less Consortium F&amp;A</td>
<td>499,940</td>
<td>499,802</td>
<td>499,816</td>
<td>499,999</td>
<td>499,950</td>
<td>2,499,507</td>
</tr>
</tbody>
</table>
Reminders Related to the NIH/AHRQ Policy for Application Submission

• Investigators now may submit a New Application, following an unsuccessful application, without concern for scientific overlap with previously reviewed applications.

• A New Application is an application that has not been previously proposed or received funding. Whether it follows an unsuccessful application or not, a New Application is neither a Resubmission Application nor a Renewal Application, and must comply with the rules for a New Application.

• Notice lists content that is NOT allowed anywhere in a new application or in the components.

Reminder: NEW NIH and AHRQ Biosketch Format

- Required for all competing and non competing applications submitted for due dates on or after May 25, 2015
- Page limit for new format is 5 pages
- Instructions, samples and FAQs are available at: [http://grants.nih.gov/grants/funding/424/index.htm#format](http://grants.nih.gov/grants/funding/424/index.htm#format)

Reminder: Simplifying the NIH Policy for Late Application Submission

• There is now a two week window of consideration after the application due date which NIH might consider your late application.

• Keep in mind NIH will not consider accepting late applications under the following circumstances:
  - RFAs or PARs that state in the Application Due Dates Field “No late applications will be accepted for this Funding Opportunity Announcement”
• New Investigator R01 applications resubmitted on special due dates.

Please review this full Notice to see reasons why late applications might be accepted or denied.

**Reminder:** NIH Modification to Guidance on Marking Changes in Resubmission Applications

- NIH has **removed** the requirement to identify 'substantial scientific changes' in the text of a Resubmission application by 'bracketing, indenting, or change of typography'.

- Effective immediately, it is sufficient to outline the changes made to the Resubmission application in the **Introduction attachment**. The Introduction must include a summary of substantial additions, deletions, and changes to the application. It must also include a response to weaknesses raised in the Summary Statement.